Navigation Links
TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
Date:4/23/2012

RESEARCH TRIANGLE PARK, N.C., April 23, 2012 /PRNewswire/ -- TeraDiscoveries, Inc., announced today a strategic relationship with Microsoft Corp. that will help it extend the reach of its drug discovery process. Microsoft is providing support and cloud computing time on Windows Azure that TeraDiscoveries will apply to identify inhibitors of 25 biological targets.

TeraDiscoveries will use its Inverse Design software that runs computational models to quickly scan virtual chemical libraries to find the strongest inhibitors of a specific biological target. The process identifies novel drug candidates that feature good clinical trial properties and demonstrate low probability of toxic side effects.

"Designing new drugs that bind to a specified protein target requires finding the best molecule in a vast chemical space. Our approach searches this space much more efficiently and cost-effectively than traditional methods," says Ed Addison, CEO of TeraDiscoveries. "Our strategic relationship with Microsoft enables us to partner with smaller pharmaceutical or medical research companies in the pursuit of these molecules."

"Windows Azure is an open and flexible cloud platform that has the scale and reliability to enable the type of computing power needed by software like Inverse Design," says Doug Hauger, General Manager, Windows Azure Business Development, Microsoft. "We're pleased to be able to support the work done by TeraDiscoveries to help advance its drug discovery process."

Companies can license Inverse Design and run it on Windows Azure to design, discover, or optimize new small molecule or peptide drugs for their targets. TeraDiscoveries also provides drug discovery services for companies seeking outside assistance.

TeraDiscoveries will be presenting Inverse Design in booth MP-10 at the Bio-IT World Conference & Expo taking place April 24 to 26, 2012, in Boston.

About TeraDiscoveries, Inc.

TeraDiscoveries is a drug discovery company located in Research Triangle Park, North Carolina. The company's Inverse Design software enables a paradigm shift to dramatically improve upon traditional drug discovery and design methods. This proprietary software combined with cloud computing enables the rapid and accurate discovery of novel drug candidates to serve as a catalyst for improved health and well-being. Visit www.teradiscoveries.com or contact Ed Addison at eaddison@teradiscoveries.com or (910) 398-1200.  

All product and company names herein may be trademarks of their respective owners.


'/>"/>
SOURCE TeraDiscoveries, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverseons Founder and SAB Member Published in PNAS
2. Inverseon Announces Positive Phase IIa Asthma Study
3. TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist
4. Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7
5. GlobalSpec Medical Equipment Design Online Trade Show and Event Draws More Than 1,100 Attendees
6. Brainlab Curve Wins Coveted Red Dot Award: Product Design 2012
7. Government Rule Designed to Limit CT Scans in ERs Is Unreliable, Invalid and Inaccurate, Says ACEP
8. Sensors in Design Summit Launches at Design West
9. Medical Design & Manufacturing Conference to be Launched in Texas in March 2012
10. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
11. Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Stock-Callers.com today presents the following Generic ... CPRX ), Sophiris Bio Inc. (NASDAQ: SPHS ), ... Therapeutics Inc. (NASDAQ: AGRX ). These companies are ... late trade on Friday, January 20 th , 2017, with ... of health care companies in the S&P 500 also were ...
(Date:1/23/2017)... , January 23, 2017 The global  anxiety disorders and ... by 2025. The rising incidence of depression worldwide is anticipated to drive the ... resulted in the declining demand for antidepressants in the recent years. ... ... Grand View Research Logo ...
(Date:1/23/2017)... DIEGO and PALMA, Spain ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company ... that the first patient has been enrolled in ... lead candidate, SNF472, for the treatment of cardiovascular ... (HD). Most ESRD patients, in the ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue of the ... study on how outdoor behavioral healthcare (OBH) – also known as wilderness therapy – ... while experiencing an increased sense of purpose both during and after treatment. , ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... a new plugin that allows sleep centers to automatically connect and initialize all ... a thin client browser plugin is quickly installed on first use and then ...
(Date:1/23/2017)... Alto, CA (PRWEB) , ... ... ... a provider of translation and localization services for life science companies, has ... and inspection organization, TÜV SÜD America. ISO 17100 is the globally recognized ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
Breaking Medicine News(10 mins):